#United States #Menlo Park #GRAIL #cancer detection #GRAL

GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference

Menlo Park, California—GRAIL, Inc. (Nasdaq: GRAL), a pioneering healthcare firm dedicated to the early detection of cancer, has confirmed its participation at the Canaccord Genuity 45th Annual Growth Conference. The event will take place in Boston on August 13, 2025, starting at 8:30 a.m. ET.

This conference presents a significant opportunity for GRAIL to showcase its groundbreaking innovations aimed at revolutionizing cancer care. The company, renowned for its mission to identify cancer at stages when it can be effectively treated, leverages advanced technologies, including next-generation sequencing and machine learning, to address the pressing challenges of early cancer detection.

Through rigorous population-scale clinical studies and cutting-edge automation, GRAIL aspires to alleviate the global burden posed by cancer. Their targeted methylation-based platform is designed to facilitate comprehensive care pathways in screening and precision oncology. This includes aspects like multi-cancer early detection specifically for symptomatic patients, risk stratification based on individual profiles, and ongoing monitoring for treatment responses and recurrence.

Attendees of the conference can access a live webcast of GRAIL’s presentation on the investor relations section of their website, with the replay available for a minimum of 30 days after the event. This engagement not only underscores GRAIL's commitment to transparency but also its dedication to informing stakeholders about ongoing advancements and strategic initiatives.

About GRAIL
Founded with the purpose of transforming cancer outcomes, GRAIL employs a unique approach to detect various high-risk cancer types in their nascent stages. The company’s innovative approach includes:

• - Multi-Cancer Early Detection: A revolutionary method identifying multiple cancer types simultaneously, enhancing the chances of successful treatment when intervention is feasible.
• - Risk Stratification: Tailored assessments that help pinpoint individuals at heightened risk, allowing for proactive measures and personalized healthcare strategies.
• - Biomarker Subtyping: This process aids in accurately classifying tumor types, thereby informing treatment plans and potential therapeutic avenues for individuals facing cancer diagnoses.
• - Monitoring and Follow-Up: Continuous assessment tools for gauging response to treatment and early detection of potential cancer recurrence, ensuring comprehensive care at every step.

GRAIL operates from its headquarters in Menlo Park, California, with additional offices strategically located in Washington, D.C., North Carolina, and international presence in the United Kingdom. This diversified footprint enables GRAIL to collaborate effectively across various regions, pushing forward its mission of combating cancer through early detection.

With the upcoming presentation at Canaccord Genuity, GRAIL is poised to emphasize the critical importance of innovative technologies in the early diagnosis and management of cancer. By leveraging both new technologies and vast clinical research, GRAIL continues to lead the way towards a future where cancer is caught early and appropriately managed, offering patients a better chance at successful outcomes.

For further information about GRAIL's initiatives and upcoming events, visit grail.com.